Autolus Therapeutics rises as blood cancer therapy meets main goal in mid-stage study

Autolus Therapeutics

02/06/2023 12:44

** Shares of cancer therapy developer Autolus Therapeutics
 AUTL.O  up 11.2% at $3.48 premarket
    ** Co reports positive top-line data from mid-stage study of
obe-cel, therapy candidate to treat a type of blood cancer 
    ** 76% patients achieved complete response to the therapy,
co says primary goal met
    ** Safety analysis show potentially best-in-class
tolerability profile - AUTL
    ** Stock up 65% YTD

 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))